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Summary Development of alcohol use disorders largely depends on the effects of alcohol on
the brain reward systems. Emerging evidence indicate that common mechanisms regulate food
and alcohol intake and raise the possibility that endocrine signals from the gut may play an
important role for alcohol consumption, alcohol-induced reward and the motivation to consume
alcohol. Glucagon-like peptide 1 (GLP-1), a gastrointestinal peptide regulating food intake and
glucose homeostasis, has recently been shown to target central brain areas involved in reward
and motivation, including the ventral tegmental area and nucleus accumbens. Herein we
investigated the effects of the GLP-1 receptor agonist, Exendin-4 (Ex4), on various measures
of alcohol-induced reward as well as on alcohol intake and alcohol seeking behavior in rodents.
Treatment with Ex4, at a dose with no effect per se, attenuated alcohol-induced locomotor
stimulation and accumbal dopamine release in mice. Furthermore, conditioned place preference
for alcohol was abolished by both acute and chronic treatment with Ex4 in mice. Finally we found
that Ex4 treatment decreased alcohol intake, using the intermittent access 20% alcohol two-
bottle-choice model, as well as alcohol seeking behavior, using the progressive ratio test in the
operant self-administration model, in rats. These novel findings indicate that GLP-1 signaling
attenuates the reinforcing properties of alcohol implying that the physiological role of GLP-1
extends beyond glucose homeostasis and food intake regulation. Collectively these findings
implicate that the GLP-1 receptor may be a potential target for the development of novel
treatment strategies for alcohol use disorders.
# 2012 Elsevier Ltd. 
Available online at www.sciencedirect.com
j our na l h omepa g e: www.e l se v ie r.c om/l oca te/ psyne ue n
Open access under CC BY-NC-ND license.* Corresponding author at: Department of Pharmacology, Institute
of Neuroscience and Physiology, The Sahlgrenska Academy at the
University of Gothenburg, Medicinaregatan 13A, SE-405 30 Gothen-
burg, Sweden. Tel.: +46 31 786 3416.
E-mail address: jorgen.engel@pharm.gu.se (J.A. Engel).
0306-4530      # 2012 Elsevier Ltd. 
http://dx.doi.org/10.1016/j.psyneuen.2012.11.009
Open access under CC BY-NC-ND license.1. Introduction
Alcohol use disorders (AUD), one of today’s major public
health problems, are characterized by compulsive drug-seek-
ing behavior and a loss of control over the intake of alcohol
(Garbutt et al., 1999). Development of AUD largely depends
1260 E. Egecioglu et al.on the effects of alcohol on the mesolimbic dopamine sys-
tem, albeit diverse additional neurobiological mechanisms
are involved (for review see (Volkow and Li, 2004; Soderpalm
et al., 2009). Elucidation of the complex neurobiological
mechanisms involved for the ability of alcohol to activate
the mesolimbic dopamine system may lead to the develop-
ment of novel treatment strategies for AUD.
Recently it has been shown that signaling systems tradi-
tionally involved in regulating food intake, including the
hunger regulating peptides such as cholecystokinin, ghrelin,
leptin and galanin, also modulates alcohol intake in rodents
(Kulkosky, 1984; Blednov et al., 2004; Lewis et al., 2004;
Rada et al., 2004; Jerlhag et al., 2009). These studies raise
the possibility that other endocrine signals regulating food
intake, such as the gut hormone glucagon-like peptide 1
(GLP-1), may play an important role for the reinforcing
properties of alcohol.
Glucagon-like peptide 1 is a circulating incretin peptide
that apart from food intake also regulates glucose home-
ostasis as well as body weight (Kreymann et al., 1987; Tang-
Christensen et al., 1996; Turton et al., 1996). This peptide is
produced in enteroendocrine L-cells of the intestinal mucosa
(Novak et al., 1987) and secreted in response to nutrient
ingestion (Brubaker and Anini, 2003). In addition, GLP-1 is
also produced in the central nervous system, specifically in
neurons in the nucleus tractus solitarius (NTS) that project
throughout the brain (Alvarez et al., 1996; Merchenthaler
et al., 1999; Baggio and Drucker, 2007; Holst, 2007). Selec-
tive GLP-1 receptor agonists, for example the GLP-1 analogue
Exendin-4 (Ex4), exenatide and liraglutide, has emerged as
novel pharmacotherapies for type II diabetes because of their
enhancing effects on glucose-dependent insulin secretion
(Holst et al., 2009), reduction of gastric emptying and glu-
cagon secretion (Matsuyama et al., 1988; Gutniak et al.,
1992; Schirra et al., 1997). The anorectic effects of GLP-1
are, at least in part, exerted via GLP-1 receptors expressed in
the hypothalamus (McMahon and Wellman, 1998) and the NTS
(Hayes et al., 2009). The fact that the GLP-1 receptor also is
expressed in the mesolimbic areas (Alvarez et al., 1996;
Merchenthaler et al., 1999), in combination with the findings
that common mechanisms regulate food and alcohol intake
(Thiele et al., 2004) imply that the GLP-1 signaling system, in
addition to homeostatic control of food intake and glucose
control, may be involved in alcohol mediated behaviors.
The present series of experiments were undertaken to
investigate the potential of the clinically available GLP-1
analogue Ex4 as a novel treatment of AUD. We evaluated
the effects of Ex4 on alcohol-induced locomotor stimulation,
accumbal dopamine release and condition place preference
(CPP) in mice. In addition, we studied the effects of Ex4 on
voluntary alcohol intake and alcohol seeking behavior in rats
that had consumed ethanol for at least eight months before
treatment.
2. Material and methods
2.1. Animals
Adult post-pubertal age-matched male NMRI mice (8—12
weeks old and 25—40 g body weight; B&K Universal AB,
Sollentuna, Sweden) were used. All mice were group housedand maintained at a 12/12 h light/dark cycle (lights on at
seven am). Tap water and food (Normal chow; Harlan Teklad,
Norfolk, England) were supplied ad libitum, except during
the experimental setups.
Adult post-pubertal age-matched male Rcc Han Wistar
rats (Harlan, Horst, Netherlands) were used for the inter-
mittent access 20% alcohol two-bottle-choice drinking para-
digm as well as operant alcohol self-administration
procedure. Rats in the two-bottle choice experiment were
maintained on a 12 h reversed light dark cycle (lights off at
10 a.m.) and rats in the operant self-administration experi-
ments were maintained on a regular 12 h light—dark cycle
(lights on at seven am). Food and water were available ad
libitum, except for short periods during initial training in the
operant self-administration paradigm. All rats were housed
individually in high Macrolon III cages covered with filter tops
(Tecniplast, Italy) and maintained at 20 8C with 50% humidity.
The study was carried out in strict accordance with the
recommendations in the Swedish Animal Welfare Act and
all experiments were approved by the Swedish Ethical Com-
mittee on Animal Research in Gothenburg and Stockholm for
the studies in mice and rats, respectively. All efforts were
made to minimize animal suffering, and to reduce the num-
ber of animals used. All animals were allowed to acclimatize
at least one week before the start of the experiments.
2.2. Drugs
The 96% alcohol (Solveco AB, Stockholm, Sweden) was diluted
to a 20% (vol/vol) solution using tap water for the two-bottle-
choice and operant self-administration experiments. Exendin-
4 (Tocris Bioscience, Bristol, UK) is a peptide with the amino
acid sequence HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSS
GAPPPS. Exendin-4 has previously been established as a
GLP-1 receptor agonist (Thorens et al., 1993) and distribution
studies show that the CNS binding of Ex4 is identical to GLP-1
(Goke et al., 1995). The Ex4 dose used in the alcohol related
experiments conducted in mice was selected based on the
results from the present locomotor study, where 2.4 mg/kg was
the highest dose that did not affect locomotor activity per se.
In the rats, the doses of 0.3 and 2.4 mg/kg were initially
selected based on previous studies (Hayes et al., 2008; Dickson
et al., 2012). However, a pilot experiment showed that the
highest dose (2.4 mg/kg) had a sedative effect in our rats that
had voluntarily been consuming ethanol for at least nine
months before the Ex4 treatment (data not shown). Therefore,
the doses of 0.3 and 1.2 mg/kg were used in the experiments
conducted in rats that had voluntarily consumed alcohol for at
least eight months before testing. In all experiments the
selected doses did not affect the rodents gross behavior.
Exendin-4 was dissolved in vehicle (0.9% sodium chloride)
and stored in aliquots at -20 degrees C before use. The Ex4
stock-solution was thawed before each treatment occasion
and administered intra peritoneal (IP) 10 min prior the start of
each experiment. A balanced or within subject design was used
for all drug challenges.
2.3. Locomotor activity experiments
Locomotor activity was recorded as described previously
(Jerlhag et al., 2006). In brief, locomotor activity was
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locomotor boxes (420 mm  420 mm  200 mm, Kungsbacka
ma¨t- och reglerteknik AB, Fja¨ra˚s, Sweden). Five by five rows
of photocell beams, at the floor level of the box, creating
photocell detection allowed a computer-based system to
register the activity of the mice. Locomotor activity was
defined as the accumulated number of new photocell beams
interrupted during a 60 min period.
The mice were allowed to habituate to the locomotor
activity box 1 h prior to drug challenge. To identify an Ex4
dose that did not affect the general gross or locomotor
behavior, a dose response study (Ex4 1.2, 2.4 or 4.8 mg/kg
or vehicle, n = 8 per treatment group) was conducted. Each
mouse received one injection 10 min before the start of the
test session. In a separate experiment, the effects of the
optimal Ex4 dose (2.4 mg/kg, IP), determined in the dose
response study, on alcohol-induced (1.75 g/kg, IP) locomotor
stimulation were investigated. Ex4 was administered 10 min
prior to alcohol and the activity registration started 5 min
after the last injection. Each mouse received one treatment
combination (vehicle/vehicle, Ex4/vehicle, alcohol/vehicle
or Ex4/alcohol; n = 8 per treatment combination) and was
only subjected to one experimental trial.
2.4. In vivo microdialysis and dopamine release
measurements
For measurements of extracellular dopamine levels, mice
were implanted unilaterally with a microdialysis probe posi-
tioned in the nucleus accumbens. The surgery was performed
as described in detail previously (Jerlhag et al., 2006). In
brief, the mice were anesthetized with isofluran (Isofluran
Baxter; Univentor 400 Anaesthesia Unit, Univentor Ldt.,
Zejtun, Malta), placed in a stereotaxic frame (David Kopf
Instruments; Tujunga, CA, USA) and kept on a heating pad to
prevent hypothermia. The skull bone was exposed and one
hole for the probe and one for the anchoring screw were
drilled. The probe was randomly alternated to either the left
or right side of the brain. The coordinates of 1.5 mm anterior
to the bregma, 0.7 lateral to the midline and 4.7 mm below
the surface of the brain surface was used for the nucleus
accumbens (Franklin and Paxinos, 1996). The exposed tip of
the dialysis membrane (20 000 kDa cut off with an o.d./i.d. of
310/220 mm, HOSPAL, Gambro, Lund, Sweden) of the probe
was 1 mm. All probes were surgically implanted two days
prior to the experiment. After surgery the mice were kept in
individual cages (Macrolon III).
The effect of systemic administration of Ex4 (2.4 mg/kg, IP)
on alcohol-induced (1.75 g/kg, IP) accumbal dopamine release
was investigated using microdialysis in freely moving mice. On
the day of the experiment the probe was connected to a
microperfusion pump (U-864 Syringe Pump; AgnTho´s AB)
and perfused with Ringer solution at a rate of 1.5 ml/min.
After 1 h of habituation to the microdialysis set-up, perfusion
samples were collected every 20 min. The baseline dopamine
level was defined as the average of three consecutive samples
before the first alcohol or vehicle (saline, IP) challenge (Time
0). This initial alcohol-challenge was given to establish that all
mice included in the experiment would respond with an
alcohol-induced release of accumbal dopamine. The chal-
lenge-induced increase in accumbal dopamine was calculatedas the percent increase from baseline. Nine consecutive 20-
min samples were collected after the initial challenge. At
190 min the mice were injected with Ex4 or vehicle (second
challenge) and 10 min later vehicle or a second injection of
alcohol (1.75 g/kg, IP) was administered (third challenge;
200 min) and followed by collection of four 20-min samples.
Collectively the following treatment groups (n = 8 in each
group) were created: alcohol—vehicle—alcohol (Alc—Veh—
Alc), alcohol—Ex4—alcohol (Alc—Ex4—Alc), alcohol—vehi-
cle—vehicle (Alc—Veh—Veh) and vehicle—Ex4—vehicle (Veh—
Ex4—Veh).
The dopamine levels in the dialysates were determined by
HPLC with electrochemical detection. A pump (Gyncotec
P580A; Kovalent AB; V. Fro¨lunda, Sweden), an ion exchange
column (2.0 mm  100 mm, Prodigy 3 mm SA; Skandinaviska
GeneTec AB; Kungsbacka, Sweden) and a detector (Antec
Decade; Antec Leyden; Zoeterwoude, The Netherlands)
equipped with a VT-03 flow cell (Antec Leyden) were used.
The mobile phase (pH 5.6), consisting of sulfonic acid 10 mM,
citric acid 200 mM, sodium citrate 200 mM, 10% EDTA, 30%
MeOH, was vacuum filtered using a 0.2 mm membrane filter
(GH Polypro; PALL Gelman Laboratory; Lund, Sweden). The
mobile phase was delivered at a flow rate of 0.2 ml/min
passing a degasser (Kovalent AB), and the analyte was oxi-
dized at +0.4 V.
After the microdialysis experiments were completed, the
mice were decapitated, and probes were perfused with
pontamine sky blue 6BX to facilitate probe localization.
The brains were mounted on a vibroslice device (752 M
Vibroslice; Campden Instruments Ltd., Loughborough, UK)
and cut in 50 mm sections. The location of the probe was
determined by gross observation using light microscopy. The
exact position of the probe was verified (Franklin and Pax-
inos, 1996) and only mice with correct placements were used
in the statistical analysis.
2.5. Conditioned place preference
To evaluate the effects of Ex4 on the rewarding effects of
alcohol, CPP tests were performed in mice as previously
described (Jerlhag et al., 2009). In brief, a two-chambered
CPP apparatus, with 45 lx illumination and distinct visual and
tactile cues was used. One compartment was defined by
black and white striped walls and by a dark laminated floor
whereas the other had a white painted wooden floor and
walls of wooden texture. The procedure consisted of pre-
conditioning (day 1), conditioning (days 2—5), and post-con-
ditioning (day 6). At preconditioning, mice were injected IP
with vehicle and was placed in the chamber with free access
to both compartments during 20 min to determine the initial
place (or side) preference. Conditioning (20 min per session)
was done using a biased procedure in which alcohol (1.75 g/
kg) was paired with the least preferred compartment and
vehicle with the preferred compartment. All mice received
one alcohol and one vehicle injection every day and the
injections were altered between morning and afternoon in
a balances design. At post-conditioning, mice were injected
with Ex4 (2.4 mg/kg, IP) or an equal volume of vehicle
solution and 10 min later placed on the midline between
the two compartments with free access to both compart-
ments for 20 min (creating the following treatment groups;
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subjected to the same procedure but received only vehicle
injections throughout the conditioning (non-alcohol condi-
tioned control group: creating the following treatment
groups Veh—Veh and Veh—Ex4).
The subsequent CPP experiment, in a separate group of
mice, aimed at investigating the effects of repeated Ex4
treatment during the conditioning on alcohol-induced CPP. In
these experiments Ex4 (2.4 mg/kg, IP) or vehicle was admi-
nistered 10 min prior to the alcohol injection on each of the
four conditioning days (creating the following treatment
groups; Veh—Alc or Ex4—Alc). In a control experiment mice
were subjected to the same procedure but received vehicle
injections instead of alcohol throughout the conditioning
(non-alcohol conditioned control group; creating the follow-
ing treatment groups; Veh—Veh and Ex4—Veh). In both these
experiments the mice were untreated at the post-condition-
ing session.
Condition place preference was calculated as the differ-
ence in % of total time spent in the drug-paired (i.e. least
preferred) compartment during the post-conditioning and
the pre-conditioning session.
2.6. Operant alcohol self-administration
2.6.1. Apparatus
Testing was conducted in standard operant conditioning
chambers (Med Associates Inc, Georgia, VT, USA) enclosed
in ventilated, sound-attenuating cubicles. Each chamber
housed two retractable levers on the right wall with a cup
liquid receptacle placed centrally between them. A house
light was present on the wall opposite the levers and
remained on at all times during the operant session. Stimulus
lights were present above each lever. An apparatus to emit a
tone under specific operant conditions was also present.
Upon correct (active) lever press(es), the stimulus light
above the active (right) lever was illuminated for 3 s and
was accompanied by a 3 s tone to reinforce availability of
reward in the dipper receptacle. Stimulus, fluid delivery, and
operant responses were all controlled and recorded by Med-
PC IV software (Med Associate Inc, Georgia, VT, USA).
2.6.2. Training phase
Rats (n = 24) were trained to self-administer 20% alcohol
without sucrose fading (Steensland et al., 2012). Four weeks
of intermittent-access to 20% alcohol in the home cage (Wise,
1973; Simms et al., 2008) were followed by two 14 h-over-
night-sessions in the operant chamber where the rats were
rewarded with a reinforcer of 0.1 ml of 20% alcohol after a
single lever press on the right (active) lever (FR1 protocol of
reinforcement). An orange scent was present in the operant
chamber and a light and a tone were presented when pressing
the active lever and served as alcohol-associated cues. Rats
were then trained daily for 45 min on the FR1 protocol on 10
consecutive days. A FR3 protocol (three active lever presses
required for reward) was then introduced and sessions were
reduced to 30 min. After approximately two months the rats
were trained only three times per week (Monday, Wednesday
and Friday) but instead the sessions were increased to
60 min. An inactive lever (no reinforcer, tone, light or olfac-
tory stimuli) was present throughout the training sessions as ameasure of nonspecific behavioral activity. The rats were
kept on the FR3 schedule for approximately five months and
thereafter subjected to extinction. To minimize the number
of animals used, in line with the recommendations in the
Swedish Animal Welfare Act, the rats participating in the
progressive ratio (PR) test in the present study underwent
testing evaluating the effects of the monoamine stabilizer (-
)-OSU6162 on cue-induced reinstatement and ethanol seek-
ing under PR schedule (Steensland et al, Biological Psychiatry
2012) before subjected to the Ex4 PR test. To prevent carry
over effects between the experiments, we allowed a wash
out period of two weeks on regular FR1 sessions three times a
week between the (-)-OSU6162 and the Ex4 tests. The rats
returned to baseline FR1 responding for 20% alcohol between
the tests (22.9  2.7 and 24.8  2.7 active lever presses
(mean of three consecutive sessions) before (-)-OSU6162
and Ex4 PR-testing, respectively). When the effect of Ex4
on alcohol seeking behavior under PR schedule was evalu-
ated, the rats had been consuming alcohol for approximately
nine months. Seven out of the 24 rats failed to meet the
criteria of <0.6 g alcohol/kg body weight per session and
were excluded from the PR test.
2.6.3. Progressive ratio testing
The PR method was adapted from (Bowers et al., 2008; Steens-
land et al., 2010). In brief, during the PR test, the response
requirement for each subsequent reward increases according
to an exponential function; PR = 5  e(0.1  number of
reinforcement previously earned)  5. The PR session started
with the cup filled with alcohol and then the PR schedule
proceeded with a schedule of 1, 2, 2, 3, 4, 5, 6, 7, 9, 10, 12,
13, 15, 17, 20, 22, 25, 38, 32, 36, 40, 45, and 50. If the rat did not
emit any lever presses for 3 min, there were 20 s timeout
(houselights off and levers retracted) followed by a compound
cue consisting of tone and light during 3 s. If the rat continued
not to emit any lever presses after the timeout, the re-cues
continued with 3 min apart for up to 5 iterations. The maximum
time each rat had on the PR test were 60 min but if the rat did
nothing during a period of 15 min or after five consecutive re-
cues, the program was turned off automatically. The breakpoint
was defined as the total number of lever presses established in
the last successfully completed ratio during the session.
Injections of Ex4 (1.2 mg/kg) or vehicle were given 10 min
prior the start of the PR test session. The PR test was
performed once a week during two weeks and each rat
received both Ex4 and vehicle in a counter balanced order.
Thus, each rat served as its own control. Regular FR1 sessions
were run on the days between the progressive ratio tests
(Friday and Monday).
2.7. Intermittent access 20% alcohol two-bottle-
choice drinking paradigm
The intermittent access 20% alcohol two-bottle-choice drink-
ing paradigm induces voluntary intake of high amounts of
alcohol (Wise, 1973; Simms et al., 2008) and pharmacological
relevant blood alcohol concentrations (Simms et al., 2008;
Carnicella et al., 2009). In brief, the rats (n = 20) were given
free access to one bottle of 20% alcohol and one bottle of
water during three 24-h-sessions per week (Mondays, Wed-
nesdays and Fridays), approximately 10 min after the lights
Figure 1 Exendin-4 attenuates alcohol-induced locomotor
stimulation and accumbal dopamine release in mice. (A) Alco-
hol-induced (1.75 g/kg IP) locomotor stimulation was attenuated
by a single injection of Ex4 (2.4 mg/kg IP) (n = 8 in each group;
***P < 0.001, as indicated in figure, one-way ANOVA followed by
a Bonferroni post-hoc test). (B) The alcohol-induced (1.75 g/kg
IP) increase in accumbal dopamine release was absent in Ex4-
(2.4 mg/kg IP) but not in vehicle-pre-treated mice (n = 8 in each
group). Arrows represent time points of injection of alcohol, Ex4
or vehicle. Initial injections of alcohol increased dopamine
release in all groups (Alc—Veh—Alc (square), Alc—Ex4—Alc (tri-
angle) and for Alc—Veh—Veh (circle)) in comparison to the group
initial receiving vehicle treatment (Veh—Ex4—Veh (rhomb)). Pre-
treatment with Ex4 prior to the second injection of alcohol
significantly attenuated the alcohol-induced increase in dopa-
mine release (Alc—Veh—Alc vs Alc—Ex4—Alc). There was no
difference in response between Alc—Veh—Veh and Alc—Ex4—
Alc (**P < 0.01 and ***P < 0.01, two-way ANOVA followed by a
Bonferroni post-hoc test). All values represent mean  SEM.
Arrow shows time for injections.
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unlimited access to two bottles of water between the alco-
hol-access-periods. Bottles were weighed at 1, 4 and 24 h
after the fluids were presented and measurements were
taken to the nearest 0.1 g. The bodyweight of each rat
was measured daily prior to bottle presentation, to allow
for calculating the grams of alcohol intake per kilogram of
body weight (g/kg). The preference for alcohol over water
(the ratio of alcohol to total fluid intake) was calculated at all
time points. Administration of Ex4 began after the rats had
voluntarily consumed high amounts of alcohol (4.5  0.3 g/
kg/24 h) for approximately eight months. The rational for
long-term alcohol exposure was to mimic the human context,
where AUD is developed following long-term cycles of con-
sumption of high amounts of alcohol and periods of absti-
nence. Each rat received each Ex4 dose or vehicle over a
three-week-test period according to a Latin square design,
with seven days between each injection. Thus each animal
served as its own control.
2.8. Statistical analysis
Locomotor activity data in the Ex4 dose response were
evaluated by a one-way ANOVA followed by Bonferroni
post-hoc tests. The microdialysis experiments were evalu-
ated by a two-way ANOVA followed by Bonferroni post-hoc
test for comparisons between different treatments and spe-
cifically at given time points. The CPP data were evaluated by
an unpaired t-test. The data from intermittent access 20%
alcohol two-bottle-choice drinking paradigm were analyzed
by one-way ANOVA, followed by a Newman—Keuls post hoc
analysis. The data from the operant alcohol self-administra-
tion was analyzed by a paired t-test. Data are presented as
mean  SEM. A probability value of P < 0.05 was considered
as statistically significant, except in the locomotor activity
testing’s where P < 0.0125 was considered significant since a
Bonferroni post-hoc test was used.
3. Results
3.1. Dose—response effects of Ex4 on locomotor
activity in mice
A statistically significant overall effect of Ex4 treatment on
locomotor activity was observed (F(3,28) = 13.08, P < 0.001;
n = 8 per group). Post hoc analysis revealed that the highest
Ex4 dose (4.8 mg/kg) increased the locomotor activity com-
pared to vehicle (P < 0.001) while the lower Ex4 doses (2.4
and 1.2 mg/kg) had no significant effect on locomotor activity
compared to vehicle (P > 0.05; Veh = 126.0  7.7, Ex4
(1.2 mg/kg) = 124.9  23.6, Ex4 (2.4 mg/kg) = 154.8  10.6,
Ex4 (4.8 mg/kg) = 268.0  26.1).
3.2. Effects of Ex4 on alcohol-induced locomotor
stimulation and accumbal dopamine release in
mice
An overall main effect of treatment was found on locomotor
activity in mice following systemic administration of alcohol
(1.75 g/kg) and Ex4 (2.4 mg/kg) (F(3,27) = 18.52, P < 0.001;n = 7—8 per group). As shown in Fig. 1A, posthoc analysis
revealed that alcohol significantly increased the locomotor
activity compared to vehicle (P < 0.001). This alcohol-induced
locomotor stimulation activity was significantly reduced by
pre-treatment with a single injection of Ex4 (P < 0.01), at a
dose that alone had no significant effect on locomotor activity
compared to vehicle treatment (P > 0.05).
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mice revealed an overall main effect of treatment
(F(3,13) = 1.14, P < 0.001), time (F(16,357) = 3.98,
P < 0.001) and a significant interaction of treatment  time
time (F(16,357) = 1.99, P < 0.001). In the first part of the
experiment the responsiveness to alcohol (1.75 g/kg) per se
was investigated. Initial injections of alcohol caused a sig-
nificant increase in accumbal dopamine release compared to
vehicle treatment at time point 60 (P < 0.001) and 80 min
(P < 0.01) for the future Alc—Veh—Alc group, and at time
point 60 min for the future Alc—Ex4—Alc (P < 0.01) and Alc—
Veh—Veh (P < 0.05) group, respectively (Fig. 1B). In the
subsequent part of the experiment, administration of Ex4
(2.4 mg/kg, at 190 min) 10 min prior to the second alcohol
injection (Alc—Veh—Alc), significantly attenuated the alco-
hol-induced accumbal dopamine release compared to vehicle
pre-treatment (Alc—Ex4—Alc) at time point 220 (P < 0.001),
240 (P < 0.01), 260 (P < 0.01) and 280 (P < 0.001), Fig. 1B. In
contrast, Ex4 when administered alone had no significant
effect on accumbal dopamine release (P > 0.05; Alc—Ex4—
Veh vs Alc—Veh—Veh).
3.3. Effects of Ex4 on alcohol-induced
conditioned a place preference in mice
In the first CPP experiment, the alcohol-induced (1.75 kg/kg)
(Alc—Veh) CPP was significantly attenuated by an acute single
injection of Ex4 (2.4 mg/kg) (Alc—Ex4) on the post-condition-
ing day compared to vehicle injection (P < 0.01, n = 8 in each
group; Fig. 2A). In the second series of CPP experiments,
conducted in vehicle conditioned mice, Ex4 per se did not
affect CPP compared to vehicle injections (Veh-Ex4:
12.5  5.3%; Veh—Veh: 11.2  4.1%, P > 0.05, n = 8 in each
group). In the third series of CPP experiments we showed that
repeated Ex4-treatment (4 injections in total; Ex4—Alc)
compared to vehicle treatment (Veh—Alc) during the 4 con-
ditioning days, blocked the ability of alcohol to induce a CPP
(P < 0.05, n = 8 in each group; Fig. 2B). In the fourth series of
CPP experiments, conducted in vehicle conditioned mice
(i.e. non-alcohol conditioned control animals), we showed
that co-treatment with Ex4 (Ex4—Veh) during conditioning
did not induce a significant CPP response compared to vehicle
co-treatment (Veh—Veh) (Veh—Veh = 0.2  9.7%, Ex4—
Veh = 20.2  5.3%, P > 0.05, n = 8 in each group).Figure 2 Exendin-4 attenuates alcohol-induced conditioned plac
condition place preference (CPP) was attenuated by an acute single
*P < 0.05, unpaired t-test). (B) Treatment of Ex4 during alcohol con
(n = 8 in each group, *P < 0.05, unpaired t-test). All values represe3.4. Effects of Ex4 on voluntary alcohol intake
using the intermittent access model in rats
The effect of Ex4 on voluntary alcohol intake was evaluated
in rats that had consumed high amounts of alcohol
(4.5  0.3 g/kg/24 h, n = 20) for eight months prior to the
test. There was an overall main effect of Ex4 treatment on
alcohol intake (g/kg) at all time-points analyzed (1 h:
F(2,19) = 18.69, P < 0.001; 4 h: F(2,19) = 12.95, P < 0.001;
24 h: F(2,19) = 8.236, P < 0.01). Post hoc analysis revealed a
significant reduction in alcohol intake following treatment
with the highest Ex4 dose (1.2 mg/kg) compared to vehicle at
all time-points (24 h: Fig. 3 A; 1 h and 4 h: Table 1). However,
the lower Ex4 dose (0.3 mg/kg) had no significant effect on
alcohol intake (24 h: Fig. 3A; 1 h and 4 h: Table 1). Further-
more, Ex4 treatment induced an overall main effect on water
intake at all time points (1 h: F(2,19) = 4.39, P < 0.05; 4 h:
F(2,19) = 8.45, P < 0.001; 24 h: F(2,19) = 5.42, P < 0.01).
Post hoc analysis revealed a significant increase in water
intake following treatment with both the high and low Ex4
dose compared to vehicle at the 24 h time point (Fig. 3B). In
contrast, at the 1 and 4 h time points, the high dose of Ex4
induced a significant decrease in water intake (Table 1). The
decreased alcohol intake and increased water intake at the
24 h time point resulted in an overall main effect of Ex4
treatment on alcohol preference (F(2,19) = 7.83, P < 0.01).
Post hoc analysis revealed a reduction in preference for
alcohol after administration of both the high and low dose
Ex4 compared to vehicle treatment at the 24 h time point
(Fig. 3C). However, no overall main effect on alcohol pre-
ference was observed at the other time points (4 h:
F(2,19) = 1.72, P > 0.05; 1 h: F(2,19) = 0.92, P > 0.05; Table
1). There was no overall main effect on the total fluid intake
following Ex4 treatment at the 24 h time point
(F(2,19) = 2.82, P > 0.05) (Fig. 3D). However, an overall main
effect was found at 4 h (F(2,19) = 25.46, P < 0.001) and at
1 h (F(2,19) = 16.67, P < 0.001). Post hoc analysis revealed a
significant reduction in total fluid intake following adminis-
tration of the high Ex4 dose (1.2 mg/kg) compared to vehicle
treatment both at 1 h and 4 h (Table 1).
To evaluate if Ex4 treatment induced a rebound increase
in ethanol consumption after the treatment was terminated,
the alcohol intake during the drinking session initiated 48 h
after Ex4 administration was evaluated. No overall maine preference in mice. (A) The alcohol-induced (1.75 g/kg IP)
 IP injection of Ex4 (2.4 mg/kg IP) in mice (n = 8 in each group,
ditioning blocked the ability of alcohol to induce a CPP in mice
nt mean  SEM.
Figure 3 Exendin-4 reduces alcohol intake in rats following eight months of intermittent access to alcohol. (A) Ex4 (1.2 mg/kg IP)
significantly reduced alcohol intake (g/kg/24 h) compared to vehicle treatment in rats that had voluntarily consumed alcohol for eight
months before the treatment. The lower dose of Ex4 (0.3 mg/kg IP) had no significant effect on alcohol consumption. (B) Ex4 (0.3 and
1.2 mg/kg IP) increased the intake of water (ml/24 h) in rats compared to vehicle treatment. (C) Ex4 (0.3 and 1.2 mg/kg IP) significantly
reduced in alcohol preference (%/24 h) compared to vehicle treatment. (D) Neither dose of Ex4 affected the total fluid intake (ml/24 h)
compared to vehicle treatment. All values represent mean  SEM (n = 20, *P < 0.05, **P < 0.01 and ***P < 0.001 compared to vehicle,
one-way ANOVA followed by Newman—Keuls post hoc test).
Table 1 Effects of two different doses of Ex4 or vehicle treatment on alcohol (g/kg), water (ml) and total fluid (ml) intake as well
as preference (%) at 1 and 4 h time points. Data represent mean  SEM (n = 20, **P < 0.01 and ***P < 0.001 compared to vehicle,
one-way ANOVA followed by Newman—Keuls post hoc test).
Treatment Alcohol Intake (g/kg) Water Intake (ml) Preference (%) Total Fluid Intake (ml)
1 h 4 h 1 h 4 h 1 h 4 h 1 h 4 h
Vehicle 0.8  0.7 1.6  0.1 1.6  0.2 3.9  0.4 62  5 58  4 4.2  0.2 9.2  0.4
Ex4
0.3 m/kg
0.7  0.1 1.4  0.1 1.5  0.2 4.1  0.5 61  4 54  4 3.8  0.3 8.7  0.5
Ex4
1.2 m/kg
0.4  0.1 *** 1.0  0.1 *** 0.8  0.2 * 2.4  0.5 ** 68  4 61  5 2.3  0.3 *** 5.6  0.7 ***
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Figure 4 Exendin-4 reduces the operant self-administration of alcohol in rats following nine months of alcohol exposure. (A) Exendin-
4 (1.2 mg/kg IP) treatment significantly reduces the number of active lever presses and (B) decreases the breakpoint (n = 16,
**P < 0.001 compared to vehicle paired t-test). All values represent mean  SEM.
1266 E. Egecioglu et al.effect on the alcohol intake was found at any time points
during the first drinking session following the Ex4 treatment
(1 h: F(2,19) = 0.73, P > 0.05; 4 h: F(2,19) = 0.26, P > 0.05;
24 h: F(2,19) = 1.67, P > 0.05).
3.5. Effects of Ex4 on alcohol seeking using
progressive ratio test
The effects of Ex4 on ethanol seeking behavior were eval-
uated using an operant self-administration paradigm under
PR-schedule in rats (n = 16). Following approximately nine
months of voluntary alcohol exposure, treatment with Ex4
(1.2 mg/kg) significantly reduced the number of active lever
presses (P < 0.01, Fig. 4A) as well as the breakpoint
(P < 0.001, Fig. 4B) compared to vehicle treatment. In addi-
tion, the number of inactive lever presses was significantly
reduced from 1.5  0.3 to 0.8  0.3 following vehicle- and
Ex4-treatment, respectively (P < 0.05).
4. Discussion
While previous studies have shown that the incretin peptide
GLP-1 is a physiological regulator of food intake and glucose
homeostasis (Baggio and Drucker, 2007; Holst, 2007), the
present results provide novel evidence that GLP-1 receptors
also are involved in regulating the reinforcing properties of
alcohol. Specifically, we found that the GLP-1 analogue, Ex4,
suppressed the alcohol-induced locomotor stimulation and
accumbal dopamine release in mice. Furthermore, our find-
ing that Ex4 attenuated alcohol-induced CPP in mice as well
as voluntary alcohol consumption and alcohol seeking beha-
vior in rats provide evidence that GLP-1 signaling is involved
in alcohol reward. Thus, GLP-1 receptors may provide a
unique target for the development of pharmacological treat-
ment strategy for AUD.
Development of AUD largely depends initially on the effects
of alcohol on the mesolimbic dopamine system (for review see
(Tupala and Tiihonen, 2004)). The present findings show that
Ex4 suppresses established alcohol-induced effects on the
mesolimbic dopamine system including alcohol-inducedlocomotor stimulation, accumbal dopamine release and CPP
(Engel et al., 1988; Sanchis-Segura and Spanagel, 2006). Glua-
gon like peptide-1 receptors are expressed in reward regulat-
ing brain areas such as the ventral tegmental area and the
nucleus accumbens (Alvarez et al., 1996; Merchenthaler et al.,
1999) and endogenous GLP-1-containing-fibers from the NTS
specifically target these reward areas (Rinaman, 2010; Alha-
deff et al., 2012). We therefore hypothesize that Ex4’s ability
to regulate the reinforcing properties of alcohol are mediated
via GLP-1 receptors within these reward nodes. Exendin-4 was
administered systemically in the present series of experi-
ments, thus it is possible that the observed Ex4 effects on
alcohol-mediated behaviors could be due to peripheral rather
than central effects. This possibility is supported by the finding
that vagal afferent signaling is required for the ability of
peripherally administered GLP-1 to reduce spontaneous meal
size (Ruttimann et al., 2009). In addition, the findings that Ex4
enhance glucose-dependent insulin secretion (Holst et al.,
2009) and that insulin modulate reward induced by psychos-
timulant drugs in rodents (for review see (Daws et al., 2011)),
indicate that the effects of Ex4 on alcohol reward could be
insulin-dependent. However, Ex4 readily crosses the blood-
brain barrier (Kastin and Akerstrom, 2003) and has anorexi-
genic properties independent of administration route (Kanoski
et al., 2011). In addition, it was recently shown that Ex4
reduces CPP for and intake of palatable food as well as
decrease the motivation for sucrose following peripheral as
well as intra-ventral tegmental and -accumbal administration
(Alhadeff et al., 2012; Dickson et al., 2012). Furthermore,
intra-accumbal injections of GLP-1 receptor antagonists cause
hyperphagia, indicating that endogenous GLP-1 signaling
within brain reward areas is important for food intake (Dossat
et al., 2011). GLP-1 signaling via GLP-1 receptors found in
other areas such as the hypothalamus and the lower brain
stem, which previously have been shown to mediate GLP-1’s
anorexigenic (McMahon and Wellman, 1998; Hayes et al.,
2009) and glucose regulating effects (Sandoval et al., 2008),
could also be of importance for alcohol reinforcement. Based
on these findings, we hypothesis that the effects of Ex4 alcohol
related behaviors seen in the present studies, are mediated
through a central mechanism. However, the exact circuits
Exendin-4 and alcohol mediated behaviors 1267through which GLP-1 receptor signaling modulates alcohol
reward and alcohol consumption needs to be further eluci-
dated.
The present study shows that GLP-1 analogues, including
Ex4, may be of clinical interest for the treatment of AUD. Our
results highlight four characteristics desirable for an AUD
medication. First, Ex4 reduced voluntary alcohol intake in
rats that had consumed alcohol for eight months before
treatment using the intermittent access 20% alcohol two-
bottle choice model (Simms et al., 2008). Importantly, this
drinking model seems to predict the efficacy of potential
novel AUD medications in a clinical population, at least for
varenicline (Steensland et al., 2007; McKee et al., 2009;
Mitchell et al., 2012). Secondly, Ex4 treatment decreased
the breakpoint for alcohol lever presses using the PR test in
the operant self-administration model, indicating that GLP-1
receptors are involved in the regulation of alcohol seeking
behavior as well as in the strength of alcohol’s reinforcing
properties. Although there was a drop in the activity at the
inactive lever following Ex4 treatment in the PR test, it
should be noted that the vehicle responding was 1.5  0.3
lever presses compared to 0.8  0.3 following the Ex4 treat-
ment. In addition, the Ex4 treatment did not affect the gross
behavior of the rats. Thus, these results indicate that the
effect on the inactive lever was not due to a general decrease
in motility. Thirdly, we showed that Ex4 did not induce a
rebound increase in alcohol intake after the treatment was
terminated, tentatively an important feature of an AUD
therapeutic. Finally, Ex4 blocked the rewarding properties
of alcohol in mice but had no effect per se on accumbal
dopamine release, locomotor activity or CPP, indicating that
GLP-1 receptors are specifically important for alcohol-
mediated behaviors and deserves to be evaluated as a
potential novel treatment target for AUD.
We hypothesize that the attenuating effects of Ex4 on
alcohol reinforcement are mediated through a direct effect
on the GLP-1 receptor. However, some studies show that Ex4
may not be selective for the GLP-1 receptor (Malendowicz
et al., 2003; Sonne et al., 2008; Barrera et al., 2009),
implying that there are other possible mechanisms of action
for Ex4 that are GLP-1 receptor independent. Given that we
have previously shown that ghrelin signaling is required for
alcohol mediated behaviors in rodents (Jerlhag et al., 2009;
Landgren et al., 2012) and that Ex4 administration has been
shown to suppress plasma levels of ghrelin in fasted rats
(Perez-Tilve et al., 2007), it cannot be excluded that our
findings are independent of GLP-1 receptor activation. How-
ever, the findings that GLP-1 receptor antagonist blocks the
ability of Ex4 to reduce the motivation to consume sucrose
(Dickson et al., 2012), supports our hypothesis that the
reinforcing properties of rewards such as alcohol are
mediated directly via GLP-1 receptors. Nevertheless, regard-
less mechanism of action, the present data are of clinical
importance since other GLP-1 analogues including exenatide
and liraglutide, are FDA-approved for diabetes mellitus and
could therefore potentially be used also for the treatment of
AUD.
The present experiments show that Ex4, in addition to
decreasing voluntary alcohol consumption, reduces water
and total fluid intake at the 1 and 4 h time points raising
the possibility that the ability of Ex4 to reduce alcohol
consumption may be due to an unselective effect on fluidintake. Another tentative explanation of the reduced fluid
intake at the 1 and 4 h time point following Ex4 treatment
could possibly be nausea since Ex4 previously has been shown
to induce a condition taste aversion at a similar dose range as
used in the present study (Kanoski et al., 2012). To exclude
this possibility we evaluated the effects of Ex4 on condi-
tioned place aversion, which has been suggested to correlate
to conditioned taste aversion (Cagniard and Murphy, 2012).
The present results show that repeated Ex4 treatment during
conditioning did not induce a conditioned place aversion in
vehicle-paired mice, indicating that the Ex4 doses used were
not aversive or induced nausea. Moreover, the findings that
Ex4 blocks parameters reflecting alcohol reward, i.e. loco-
motor stimulation, accumbal dopamine release and CPP,
imply that the rewarding properties of alcohol were speci-
fically targeted. In accordance with these findings, recent
studies have shown that Ex4 attenuates amphetamine- as
well as cocaine-induced locomotor stimulation in rodents
(Erreger et al., 2012; Graham et al., 2012). Taken together
with the notion that the mesolimbic dopamine system
increases the incentive value of motivated behaviors (Robin-
son and Berridge, 1993), it is possible that GLP-1 analogues
may decrease the incentive value for motivated behaviors in
relation to alcohol and other drugs of abuse. Supportively,
GLP-1 analogues have been found to reduce the motivation
for palatable food (Raun et al., 2007; Dickson et al., 2012),
further supporting a role for GLP-1 signaling in drug-induced
reward and possibly in the pathophysiology of AUD. Addi-
tionally, repeated co-treatment with Ex4 during the alcohol
conditioning phase and acute Ex4 treatment on the test day,
blocked alcohol-induced CPP in mice providing evidence that
GLP-1 receptors are involved in both the acquisition and
retrieval of reward related memory, which are other impor-
tant aspects of the addiction process.
Our present findings show, to our knowledge for the first
time, an involvement of the GLP-1 receptors in alcohol
reinforcement. These results support previous studies show-
ing that gut-brain signaling systems has the ability to regulate
the intake of both food and alcohol (Thiele et al., 2004). For
example, other endocrine signals from the periphery and the
gut including leptin and cholecystokinin reduces, whereas
galanin increases, food as well as alcohol consumption (Bled-
nov et al., 2004; Lewis et al., 2004; Rada et al., 2004). In
addition, the orexigenic peptide ghrelin is required for alco-
hol-reward, alcohol intake as well as for the motivation to
consume alcohol (Jerlhag et al., 2009; Kaur and Ryabinin,
2010; Landgren et al., 2012). Supportively, gastric bypass has
recently been shown to reduce alcohol intake in both humans
and rats (Davis et al., 2012). A finding that has been corre-
lated to reduced ghrelin and increases GLP-1 plasma levels
(Davis et al., 2012). However, population studies, without
correlations to plasma levels of these gut-brain hormones are
inconclusive and show that gastric bypass can reduce,
increase or have no effect on alcohol consumption in humans
(for review see (Ertelt et al., 2008)). Collectively, the present
findings raise an important question regarding the physiolo-
gical role of gut—brain signals and their ability to influence
not only food intake but, also having a broader role in
modulating the reward system in general and reward related
processes in relation to alcohol in particular. These endocrine
signals may therefore be potential target for development
of novel treatment strategies for of AUD. Interestingly,
1268 E. Egecioglu et al.selective GLP-1 receptor agonists are used as treatments for
type II diabetes because of their enhancing effects on glu-
cose-dependent insulin secretion (Holst et al., 2009), reduc-
tion of gastric emptying as well as on reduction of glucagon
secretion (Matsuyama et al., 1988; Gutniak et al., 1992;
Schirra et al., 1997).
In conclusion, our present results showing that Ex4 attenu-
ates alcohol-induced locomotor stimulation, accumbal dopa-
mine release and CPP as well as reduces alcohol intake and
alcohol-seeking behavior in rodents, indicate that GLP-1
analogues deserves to be evaluated as potential therapeutics
for AUD, an entirely novel aspect.
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